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ABSTRACT 
Objective: To evaluate the incidence of PTLD, the risk factors and the impact of this 
complication on survival outcomes in a large cohort of LTX recipients at a single institution. 
Background: LTX has been accepted as a therapeutic option for patients with end-stage liver 
disease since 1983, in large part due to the availability and reliance on the use of non-specifically 
directed immunosuppression. However, as predicted and subsequently verified in 1968, an 
increased incidence of certain de novo malignancies has been observed, particularly with regards 
to lymphoid neoplasms. While many reports have confirmed and clarified the nature of PTLD, 
the literature is fraught with conflicting experience and outcomes with PTLD. 
Patients and Methods: Four thousand consecutive patients, who underwent LTX between 
February 1981 and April 1998, were included in this analysis and were followed to November 
2001. The effect of recipient age at the time of L TX, recipient gender, diagnosis, baseline 
immunosuppression, grading of PTLD,and association with Epstein-Barr virus (EBV) were 
compared. The causes of death were also examined. Treatment for PTLD varied over the 20-
year period, but all included massive reduction or elimination of baseline immunosuppression. 
Results: The one year patient survival for L TX patients with PTLD is 85%, while the overall 
patient survival for the entire cohort is 53%. The actuarial 20-year survival is estimated at 45%. 
The overall median time to PTLD presentation was 10 months and children had an incidence of 
PTLD that was three-fold higher than adults. Patient survival was better in the pediatric age 
group, in patients transplanted in the era of Tac immunosuppression, in patients with 
polymorphic PTLD, and those with limited disease. Interestingly, neither the presence or 
absence of EBV, nor the timing of PTLD presentation, appeared to influence overall patient 
survival. LTX patients transplanted for alcohol-related liver disease had similar incidence of 
PTLD but had a higher risk of mortality. 
Conclusion: While PTLD continues to pose problems m LTX, improvements in patient 
survival have been observed over time. While it is too early to assess the impact of new 
advances in prophylaxis, diagnosis, and treatment, such approaches are based upon an increased 
knowledge of the pathophysiology ofPTLD. 
INTRODUCTION 
Transplantation of solid organs has been successful, in large part due to the development of 
immunosuppressive regimens that have controlled the recipient immune system from rejecting 
the allograft. By suppressing recipient T lymphocytes with cyclosporin (esA) or tacrolimus 
(Tac), or reversing rejection with anti-lymphocyte agents, such as ATGAM or OKT3, rejection 
has become a rare cause of allograft loss (1). However, the penalty for the non-specific nature of 
immunosuppression is the susceptibility of the recipient to the development of opportunistic 
infections (including viral, fungal and protozoal organisms), as well as the increased risk of 
developing malignancies (2). 
Post-transplant lymphoproliferative disease (PTLD) can be considered, for the most part, an 
opportunistic infectious complication that: arises after transplantation, usually involving the 
Epstein-Barr virus (EBV) (3). Lymphoid tumors were first described in transplant patients in 
1968 and were called "reticulum cell, sarcomas"; a subgroup of these was termed 
"pseudolymphomas" in recognition of their ability to undergo regression after reduction of 
immunosuppression (4-6). PTLD describ~s a heterogeneous group of lymphoproliferative 
diseases ranging from benign polyclona1 B cell proliferation, as seen in acute EBV infections 
(e.g. mononucleosis), to a relatively maligJilant monoclonal lymphomatous lesion. In addition, 
the spectrum of presentations varies from localized to disseminated involvement, and nodal to 
extranodal, including the allograft organ itself (7, 8). 
The risk factors and incidence of PTLD, as well as outcomes after the development of this 
complication in LTX are not clearly appreciated, in part due to variations in the study population, 
changing definitions of PTLD, improved detection methods and higher index of suspicion. The 
current study will assess the incidence of PTLD, the risk factors and the impact of this 
complication on survival outcomes in a large cohort of L TX recipients at a single institution. 
MATERIALS AND METHODS 
The study subjects are first 4000 consecutive patients who underwent LTX since the inception of 
program at the University of Pittsburgh starting in February 1981 to April 1998, and have been 
described elsewhere (1). Briefly, this group of patients received a total of 4947 allografts. Nine 
hundred and twenty two patients in our overall LTX experience were excluded from analysis, 
either because they were transplanted at the V A Medical Center, received combined liver and 
intestinal allografts, or did not have a minimum of three years follow-up. The mean follow-up 
was 11.8 ± 3.9 years (median 11.7: range 3 to 20 years). There were 2172 (54.3%) males and 
1828 (45.7%) females. The study populations were analyzed based on the age of the recipient at 
the time of transplant (i.e. adult vs. pediatric), and into two timeframes (based on the routine use 
of CsA or Tac). The demographics of the patients studied, with respect to immunosuppression, 
age, and follow-up time are shown in Table 1. The follow-up between patients on CsA was 
significantly longer than for Tac (p<0.0l). 
A single experienced transplant pathologist (MN), in a blinded fashion, reviewed all PTLD 
specimens that were available from the beginning of the program. Since 1991, in situ 
hybridization with probes to detect the EBER-1 gene was added to document the presence or 
absence ofEBV in PTLD specimens (9). The grading scoring system used was adapted from the 
Society for Hematopathology Workshop held in 1995, which defined the spectrum of recognized 
PTLD (10). A summary of the characteristics used define reactive or early lesions, polymorphic 
PTLD, and lesions which appeared to represent lymphomas or hematopoietic neoplasms, 
including a category for lesions such as plasmacytomas, T cell rich B-celllymphomas, and T cell 
lymphomas under the umbrella term of PTLD, is shown in Table 2. 
All patient information was collected prospectively and entered into the Thomas Starzl 
Transplantation Institute Electronic Data Interface for Transplantation (EDIT) which store 
demographics, laboratory tests, medications, pathology, and other relevant clinical information 
by interfacing with all hospital information systems and also include manually entered data from 
external sources. Data for analysis was rendered anonymous by stripping it of unique patient 
identifiers by an "honest broker", according to the requirements of the exempt University of 
Pittsburgh Institutional Review Board approved protocol (IRB#020 I 77). 
Statistical Analysis 
Kaplan-Meier estimates were used to calculate survival curves. Differences in survival curves 
were compared using log rank statistics. Differences in proportions were tested using chi square 
test (or Fisher exact test). "P" values less than 0.05 were considered statistically significant. 
RESULTS 
Incidence of PTLD 
Of the 4000 LTX patients studied, a total of 170 patients (4.3%) were found to have PTLD, 10 of 
which were only diagnosed or confirmed at the ;time of autopsy (11). The incidence of PTLD 
was significantly higher in children (9.7%) as compared to adults (2.9%) (p<0.01). Although the 
overall incidence of PTLD was similar betweenCsA and Tac treated patients, the incidence of 
PTLD in the pediatric group was higher under Tac than CsA (12.6% vs. 7.7%, p=0.06), while the 
incidence of PTLD in adults was no different based on immunosuppression (3.1 % CsA vs. 2.6% 
Tac). The difference in pediatric PTLD incidence is in part due to a significantly higher early 
mortality in the CsA group vs. the Tac group (32% vs 15% at three years post-LTX, 
respectively), thus reducing the at-risk population (12). The diagnosis-associated incidence of 
PTLD is shown in Table 3. The higher rate of PTLD in the "Metabolic" and "Biliary Atresia" 
group reflects the preponderance of children for these two indications. 
Timing of PTLD 
The overall median time to development of PTLD was 10 months - this was significantly shorter 
in children compared to adults (8.1 months vs. 15 months, p=0.02). Within the adult population, 
CsA was associated with a shorter time to PTLD development compared to Tac (6.1 months vs. 
23.6 months, p=O.Ol), while the opposite was true for the pediatric population (27 months CsA 
vs. 4.7 months Tac). Figure 1 demonstrates the wide range in the timing to developing PTLD. 
Presentation of PTLD 
In hematologic malignancies, staging of disease correlates with treatment response and survival, 
but little data exists in the area of PTLD. Table 4 summarizes the number of patients with single 
or multiple site involvement with PTLD. A slightly greater number of patients presented with 
single site involvement (58%) compared to multiple sites (41%) (p=n.s.) and this was no 
different amongst the age or immunosuppressive categories. The locations of PTLD are shown 
in Table 5. Lymph nodes were the most predominant site involved (35%), in children this was 
higher (41%) compared to adults (31%). Gastrointestinal involvement was seen in 25%, while 
the liver and spleen was involved in 16% of cases. eNS involvement was present in only 4% of 
cases. 
Grading of PTLD 
Using the grading system adopted by the Society for Hematopathology and revised by European-
American Lymphoma Group (10), 148 of the 170 PTLD were classified. As shown in Table 6, 
12% were considered as "Eady Lesions" Grade I, 35% were classified as "PTLD -
Polymorphic" Grade II, 43% were categorized as "PTLD - Monomorphic" Grade III, and 1 0% 
were classified as "PTLD - Other" Grade IV. While there were no notable differences in the 
grading based on type of immunosuppression, there was a notable difference between adults and 
children. Sixty-eight percent of pediatric PTLD were classified as Grades I or II, while 70% of 
adult PTLD were classified as Grades III or IV (p<O.Ol). Two cases in Grade IV were T-cell 
PTLD. 
Role ofEBV 
With the availability of probes to detect the EBV-encoded small RNA, EBV can be detected in 
paraffin-fixed specimens using in situ hybridization (9). EBER was positive in 80% of samples, 
while EBER was not detected in 20% of the 104 PTLD samples studied. Of interest was that 
98% of pediatric PTLD were EBER positive, while only 68% of adult PTLD were EBER 
positive. 
Patient Survival 
The actuarial patient survival for entire population ofPTLD patients at 1,5, 10, 15 and 20 years 
was 85, 69, 55, 47 and 45 percent respectively, as shown in Figure 2. While there was numerical 
difference in survival with women having a better survival than men, this was only evident at 10 
years after PTLD diagnosis and did not reach statistical significance. Long-term survival rates 
for pediatric patients with PTLD were better than for adults (60% pediatric at 15 years, compared 
to 39% for adults), but did not quite reach significant difference (p=O.06) (Figure 3). As a 
reflection of both the impact of improvements over time and with immunosuppression, survival 
in the Tac group was significantly better than for CsA (60% for Tac, vs. 40% for CsA by 12 
years) (p<0.02) (Figure 4). Other factors that appeared to have a positive effect on survival 
included: Grade I PTLD vs. Grades II-IV PTLD (p=0.04) (Figure 5), and single site vs. multiple 
site (p<O.02) (Figure 6). No effect of EBER positivity, or time to development of PTLD was 
apparent on patient survival (data not shown). As noted in Table 3, patients transplanted for 
alcohol related liver disease, who deve1op.ed PTLD, had a higher risk of dying. 
Causes of Death 
A total of 80 patients (47.1 %) died during the entire follow-up period. The causes of death are 
shown in Table 7. PTLD was thought to be the major contributing cause of death in 44% (n=35) 
patients with PTLD. Infection and multisystem organ failure accounted for the second most 
common causes of death, comprising 28% of all deaths. This was followed by recurrent or de 
novo cancers (5%) and recurrent disease (5%). 
Treatment 
As one would expect, treatment for PTLD varied considerably over the twenty-year period. 
However, the mainstay of treatment was immunosuppressive drug reduction or discontinuation 
in all cases where this could be documented (the exceptions are those patients in whom the 
diagnosis of PTLD was not made ante mortem). Other treatments included: antiviral therapy, 
e.g. acyclovir or ganciclovir, in 821122 cases (67%), followed by chemotherapy or radiotherapy 
(31 (%), surgery (17%) and more recently, the use of anti-B cell monoclonal antibodies (11 %). 
Immunomodulation or immunotherapy was attempted in 6% of cases. 
DISCUSSION 
The overall incidence of PTLD in LTX patients is estimated to occur at 2-3% overall (2, 8, 13, 
14). However, there are populations of LTX recipients, which can be identified as "high-risk" 
patients. These include: lack of previous EBV infection (i.e. EBV seronegative); pediatric 
transplant recipients; and those that receive anti-lymphocyte antibodies. These risk factors are at 
least additive, so that in the pediatric LTX transplant recipient, who is EBV seronegative, and 
requires anti-lymphocyte antibodies is extremely high-risk (PTLD risk up to 30%) (8, 15-17). 
Other risk factors for PTLD have been implicated; such as HCV co-infection in liver transplant 
recipients (18, 19). We did not observe this correlation in our patients - the incidence of PTLD 
in the HCV+ group was 3.01 % vs. 2.85% ofHCV- adult LTX recipients. 
Prior to 1981, lymphoid tumors in transplant patients were uniformly referred to as 
immunoblastic satcomas. That year, Frizzera and colleagues :from the University of Minnesota 
examined tumors from a small number of renal transplant recipients (20). They observed several 
forms of lymphoproliferation, which had not been previously described and applied the term 
"pob:rgorphic" to emphasize the heterogeneity in size and shape of the tumor cells. Ancillary 
studies showed the tumors to be comprised of B-Iymphocytes. They also stressed that the 
behavior of PTLD could not be reliably predicted by pathologic studies alone. In 1988, we 
reported our experience with PTLD observed in the University of Pittsburgh transplant 
population. We were unable to discern :any significant difference in the clinical behavior of the 
two types of polymorphic lesions and combined them under the heading of polymorphic PTLD. 
In contrast, lesions, which resembled typical non-Hodgkin's lymphomas, were recognized as a 
variant of PTLD and the term, monomorphic PTLD, was introduced to distinguish these lesions 
from polymorphic PTLD (7). As shown in this study, we were unable to show an association 
between poorer outcomes and more advanced grades of PTLD, although the "early" lesions 
appeared to have a better survival rate. However, it has been suggested that further 
categorization of PTLD is possible based on combined pathologic and molecular features -
specifically, that more recalcitrant tumors have a monomorphic histology, are monoclonal, and 
contain rearrangements of the c-myc proto-oncogene (21). We did not routinely perform 
analysis for chromosomal rearrangements in our experience, however others and we have clearly 
shown that gene analysis can help to assess c10nality and possibly prognosis (21-24). Broader 
application of molecular techniques may help to distinguish lower risk from higher risk PTLD 
for purposes of treatment. 
Treatment of PTLD is one of the most controversial areas in solid organ transplantation (12). 
The lack of a clear consensus in the management of patients with established PTLD stems, is in 
part, a result of the limited understanding of its pathogenesis, the lack of characterization of 
PTLD, and the specific immune defects associated with PTLD. Nevertheless, based on single 
center reports, four major areas of treatment should be considered: a) reduction of 
immunosuppression; b) chemo- and biologic therapy; c) anti-B cell monoclonal antibody 
therapy; and d) cell based therapies. We believe that the comparatively good outcomes for PTLD 
reported here, and that span the 20 year existence of this program hinges on the principle of 
recovery of the recipients immune response leading to modulation of the PTLD, generally by 
reducing or eliminating immunosuppression (6). Our current algorithm for treatment in 
documented or suspected PTLD is the imitial intervention of reduction in immunosuppression. 
However, how much reduction, for how long, and how to predict the response to such reduction 
is unknown. o~ession of monoclonal and p~lonallesions following reduction of the dose of 
t --......--
immunosuppression ranges from 23% to 50% (6, 12). Potential consideration for the level of 
immunosuppression reduction should assess the following: the severity of illness, the location 
and presentation of PTLD, the length and type of immunosuppressive therapy, and the 
immunohistochemical and molecular characterization of the PTLD. At the ASTP/ASTS 
4.. Workshop on PTLD (12), ~1!Ke consensus in critically ill patients with extensive disease is to 
decrease prednisone to a maintenance dose of 7.5-10 mg/day and all other immunosuppression 
stopped. If there is no response or the response is not adequate within 7-21 days, then more 
aggressive interventions should be considered. In addition, in the less critically ill patient with 
limited disease, the initial management strategy should include reduction of esA or Tac and 
prednisone by at least 50%, while azathioprine or MMF should be discontinued. After a 14-day 
trial of decreased immunosuppression, a further decrease of 25% can be considered. Should 
clinical urgency or failure of "conservative" therapy develop, chemotherapy using a lymphoma 
protocol has generally been adopted (12, 25-27). Alternatively, promising results using anti-B 
cell monoclonal antibodies have been reported, beginning with the initial results of Fischer and 
coworkers using a combination of anti-CD21 and anti-CD24 monoclonal antibodies (28). The 
availability of anti-CD20 monoclonal antibody, which targets most B-cells, has been shown to 
have promising preliminary results (29, 30). 
The results of this approach reveal that short-term and long-term patient survival were not as 
dismal as reported in other series (14, 26). Nevertheless, the decline in survival was 
approximately 6% per year in the adult PTLD population and 4% per year in the pediatric PTLD 
population, worse than that observed in the LTX group as a whole (approximately 3.5% and 
1.5% per year decline, respectively) (1). The fact that PTLD contributed to 44% of deaths in 
patients afflicted with PTLD highlights the need for advances in prophylaxis, detection, 
treatment of PTLD, as well as a better understanding of other risk factors associated with this 
disease. We also note that while L TX patients transplanted for alcoholic liver disease had 
similar risks for PTLD, their long-term mortality rate was significantly higher (87%) compared 
to 50% in non-alcoholic LTX patients. It may be that the reported karotypic chromosomal 
lymphocyte aberrations associated with ethanol (31) may potentiate the known effect ofEBV in 
causing chromosomal translocation (reviewed in 8). 
Green and colleagues at the University of Pittsburgh have initiated a study examining the use of 
high titer anti-EBV intravenous immunoglobulin for EBV-associated PTLD in high-risk 
pediatric recipients (32). McDiarmid and others from UCLA have suggested that the use of 
intravenous ganciclovir in high-risk EBV+ donors to EBV- recipients may prevent subsequent 
PTLD (33). 
Rowe and coworkers examined the utility of EBV viral loads as a means to monitor patients at 
risk for PTLD (34, 35). Others have also suggested that EBV monitoring can be useful in high-
risk transplant recipients (36). The Montpellier group has suggested that detection of persistent 
monoclonal immunoglobulins in LTX recipients was associated with a 23% incidence of PTLD 
(37). Certainly, if PTLD can be detected preemptively or while still in an "early" stage, the 
outcomes would likely be better. 
Cell based immunotherapy holds promise for the treatment of PTLD, however the use of 
adoptive cellular immunotherapy using IL-2-stimulated LAK (lymphokine activated killer) cells 
was associated with a response rate of only 30% in refractory PTLD (38). Targeted approaches 
using EBV -specific T effector cells have been used in patients with PTLD following bone 
marrow transplantation since, in these patients, although the PTLD arises from donor B-cells, the 
EBV -specific effector T cells can be obtained from the donor, who is not under the effect of 
immunosuppression (39). Similar approaches to generate EBV-specific cytolytic T cells (CTL) 
in high risk EBV seropositive transplant recipients has also shown promise as a means to 
preemptively treat patients with elevated EBV viral load (40). In the case of an EBV 
seronegative solid organ transplant recipient, there are significant technical limitations in priming 
ex vivo EBV-specific CTL and may limit their expansion and subsequent clinical use. However, 
recent advances in understanding the biology of antigen presenting cells and especially that 
growth factors may make this approach possible in the future for treating solid organ transplant 
recipients (41). 
There is increasing recognition that EBV-negative PTLD is a separate entity - these tumors tend 
to arise later in the post-transplant course (42, 43), and have been reported to have a higher 
frequency of c-myc rearrangements (44). Although we have seen an increasing detection of 
EBV negative PTLD (45), as noted in this study, we did not detect any impact on clinical 
outcomes, recognizing that this entity appears to be mostly restricted to adult transplant 
recipients. Thus far, no etiologic agent has been found. 
Table 1: Patient Demographics 
Median Follow-up: 
Mean Follow-up: 
Mean Follow-up CsA: 
Mean Follow-up Tac: 
Total patients: 
Males: 
Females: 
Total CsA: 
Total Tac: 
Children (Age <18 yrs): 
Children CsA: 
Children Tac: 
Adults (Age >18 yrs): 
Adult CsA: 
Adult Tac: 
11.7 years 
11.8 ± 3.9 years 
15.2 ± 2.23 years 
8.9 ± 2.5 years 
4,000 
2,172 (54%) 
1,828 (46%) 
1,830 (46%) 
2,170 (54%) 
808 (20%) 
482 
326 
3,192 (80%) 
1348 
1844 
Table 2: Classification system for PTLD* 
Grading 
o 
1 
2 
3 
4 
Description 
EBV lymphoadenititis, hepatitis, not classified as PTLD 
Early lesion, low-grade mononucleosis, plasma cell 
hyperplasia 
Polymorphic, diffuse B-cell hyperplasia (PDBH) and 
polymorphic B-celllymphoma (PBC) 
Monomorphic or lymphomatous PTLD or lymphoma, 
Immunoblastic lymphoma (IBL), diffuse large cell B-cell or 
diffuse small cell noncleaved (Burkitt-like) 
Other Hodgkins-like PTLD, plasma cell lesions, plasmacytoma, T cell 
PTLD 
* Adapted from Harris et al (10) 
Table 3: Incidence of PTLD Based on Grouping for L TX Indications 
no. of 
,Diagnosis Cases PTLD % ofPTLD % survival 
Alcoholic 567 16 2.8 12.5 
HCV+NANB 655 20 3.1 50 
Malignancy 301 5 1.7 40 
PBC+PSC+AI 829 31 3.7 64.5 I 
HBV 219 3 1.4 66.7 
Metabolic 227 17 7.5 41.2 
ailiery Atresia 429 37 8.6 59.5 
Fulminant Failure 124 7 5.6 71.40 
bther 649 34 5.2 52.9 
[Total 4000 170 4.3 52.9 
Table 4: Extent ofPTLD Involvement - Single vs. Multiple Sites 
*Tonsil and/or adenoids and/or cervical lymph node in any combination or alone, GI 
single or muhiple lesions with or without mesenteric nodes were considered as one site. 
Table 5: Location ofPTLD Involvement 
Children Adults Total 
Total Total 
CsA Tac Children CsA Tac Adult n (%) 
.ymph node 26 24 50 23 23 46 96 (35.2) 
~f 10 18 28 17 22 39 67 (24.6) 
Jver. Spleen 10 15 25 11 8 19 44 (16.2) 
Pulmonary 8 2 10 8 11 19 29 (10.7) 
iCNS 3 2 5 1 5 6 11 (4.0) 
Other 4 1 5 9 11 20 25 (9.2) 
Table 6: Grading of PTLD* 
*Using criteria described by Harris et al (10) - a total of 148 cases available. 
Table 7: Causes of Death 
Causes Number % 
PTLD 35 44 
Infection 18 23 
Multisystem Organ Failure 4 5 
Recurrent disease, Graft Failure 4 5 
Recurrent/De Novo Malignancy 3 4 
Gastrointestinal 3 4 
Cardiac System 3 4 
Respiratory System 2 2 
Trauma, motor vehicle accident 1 1 
Intra cranial bleed 1 1 
Unknown causes 6 7 
Total 80 
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Figure 1: Incidence ofPTLD as a measure oftime after L TX. Y-axis represents actual 
number of cases. 
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